ME (23andMe Holding Co) סך נכסי הפעילות העסקית

23andMe Holding Co. (ME) is implementing eco-friendly materials in diagnostics and strictly protects the privacy of genetic codes. The business relies on the monetization of biodata arrays and drug discovery. This price action reflects total assets at 465.17. The company is currently transitioning to a subscription model for AI analytics, although the potential of its own therapeutic developments will only be realized in the long term.

For a long-term investor, the reliability of 23andMe Holding Co. (ME) is determined by the value of resources reverse-calculated via ROA as the sum of equity and liabilities, which allows for tracking the expansion dynamics of the DNA database—the company's key leverage in deals with pharmaceutical behemoths—through the current level of gross assets on GURU.Markets, where any downward trend reversal signals a decline in the business's fundamental stability.